Nivolumab plus Ipilimumab May Be a New First-Line ...
Nivolumab and low-dose ipilimumab show durable clinical benefit for MSI-H/dMMR metastatic CRC patients, with 84% tumor burden reduction, 74% PFS, and 79% OS at 24 months. The combination, well-tolerated with a 69% response rate, may offer a new first-line therapy option.
Reference News
Nivolumab plus Ipilimumab May Be a New First-Line ...
Nivolumab and low-dose ipilimumab show durable clinical benefit for MSI-H/dMMR metastatic CRC patients, with 84% tumor burden reduction, 74% PFS, and 79% OS at 24 months. The combination, well-tolerated with a 69% response rate, may offer a new first-line therapy option.